Research programme: cancer immunotherapeutics - Novartis

Drug Profile

Research programme: cancer immunotherapeutics - Novartis

Alternative Names: Cancer immunotherapy - Novartis

Latest Information Update: 20 Feb 2014

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Immunostimulants; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 17 Feb 2014 Early research in Cancer in Switzerland (unspecified route)
  • 17 Feb 2014 Novartis acquires CoStim Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top